Director, Pharmacoepidemiology
Eli Lilly and Company
Kristin Meyers, PhD MPH. Director - Pharmacoepidemiogy in Global Patient Safety at Eli Lilly and Company.
Responsible for pharmacoepidemiology needs related to safety outcomes within the autoimmune therapeutic area at Lilly - including the design, conduct, and reporting of observational post-authorisation safety studies. Also point of contact and experienced with other aspects of pharmacovigilance including risk managment plans (RMP), signal detection and evaluation, REMS, risk minimisation effectiveness assessments, and periodic safety update reports (PSUR-PBRER).
